Figure 6.
ALCAM suppressed myeloma clonogenicity in vivo in mouse models. (A) Human MM xenograft mouse model was established. Tumor growth after inoculation was examined. (B) Scheme graph showing the CK and AK constructs. (C) western blotting of virus-infected NIH3T3 cell lysates. The results are quantified in the right panel. The data were obtained from 3 independent experiments and shown as the mean ± SD. (D) Scheme graph showing the procedure of adoptive plasma cell cancer model generation. (E) Immunohistochemistry of CD138 in mice BM from non-cancer-bearing mice (NC), CK mice, and AK mice (2 of 5). (F) Flow cytometry analysis of mouse BM cells. The number indicates GFP+/CD138+ cell ratio (left, 2 of 5), and result quantification (right). (G) Mouse survival after adoptive transplantation. All data in bar graphs were assessed by 2-tailed Student t test. *P < .05; **P < .01.

ALCAM suppressed myeloma clonogenicity in vivo in mouse models. (A) Human MM xenograft mouse model was established. Tumor growth after inoculation was examined. (B) Scheme graph showing the CK and AK constructs. (C) western blotting of virus-infected NIH3T3 cell lysates. The results are quantified in the right panel. The data were obtained from 3 independent experiments and shown as the mean ± SD. (D) Scheme graph showing the procedure of adoptive plasma cell cancer model generation. (E) Immunohistochemistry of CD138 in mice BM from non-cancer-bearing mice (NC), CK mice, and AK mice (2 of 5). (F) Flow cytometry analysis of mouse BM cells. The number indicates GFP+/CD138+ cell ratio (left, 2 of 5), and result quantification (right). (G) Mouse survival after adoptive transplantation. All data in bar graphs were assessed by 2-tailed Student t test. *P < .05; **P < .01.

Close Modal

or Create an Account

Close Modal
Close Modal